August 26, 2026; By rarebluemoon
Patients ask me some version of this almost weekly: does running my blood through a machine actually get the bad stuff out?
Answering properly means starting with where blood filtration came from.
Start with the therapy nobody argues about. In hemodialysis, blood travels out of the body through a filter and back again, typically through two needles in the arm. Clinicians have called that filter an artificial kidney for decades.
Two features of the circuit are worth holding onto. The mechanism is understood, so we know what is removed and why that helps. And the indication is narrow: nobody suggests dialysis for someone with working kidneys who feels run down. A defined mechanism paired with a defined indication is what separates established therapy from an interesting idea.
Blood filtration did not stop at the kidney. Apheresis, separating blood into components and removing one of them, now spans plasma exchange, red cell exchange, white cell removal, and more.
The American Society for Apheresis publishes graded guidelines that assess each use of apheresis separately, and the current ninth edition runs to 91 fact sheets and 166 categorized indications, each with its own evidence grade. The society did not rule on whether apheresis works. It ruled, one condition at a time, on whether apheresis works for that condition, with some indications first-line and others graded against use entirely.
Lipoprotein apheresis shows that the standard is being met. Patients who inherit familial hypercholesterolemia and cannot bring LDL down with medication have lipoproteins physically removed from circulating blood, and the FDA has approved this for defined patient groups using specific LDL thresholds and documented arterial disease.
A measurable target, a defined population, criteria you either meet or you do not. Any clinician telling you a filtration technology is simply good for you has skipped the only question that matters: good for what, and how well established is that?
Mechanically, EBOO belongs to the family above: blood drawn from one vein, moved continuously through an external circuit, returned through another. That architecture is not exotic. What makes it different is that the ozone is not doing the filtering. It is doing something else, and confusing those two ideas produces most of the bad explanations patients receive.
When blood meets a controlled oxygen and ozone mixture outside the body, the ozone does not persist. It reacts almost immediately with antioxidants, lipids, and proteins in plasma, generating reactive oxygen species and lipid oxidation products that act as secondary messengers, transiently raising oxidative stress in a way that appears to prompt the body’s own antioxidant and immune responses.
That is not a hand-wave. It is measurable. Work published in Redox Report on the EBOO technique found that after a session, thiobarbituric acid reactants rose four to fivefold with a proportional fall in plasma protein thiols, without appreciable red cell hemolysis.
That last clause deserves attention, because the most common criticism of blood ozonation is that any visible change is simply damaged red cells. Measured directly, the oxidative signature appeared in plasma proteins while erythrocytes stayed intact. The same authors proposed those markers for routine monitoring, a level of quality control most clinics offering this do not attempt.
Dose is the entire game. Ozone acting on human blood produces a hormetic dose-response relationship: a controlled low concentration behaves very differently from a high one. Too much is toxic. That is not a reason to avoid the therapy; it is the reason concentration and equipment specification are not details to wave past.
Conventional ozone autohemotherapy draws a single batch of roughly 250 mL, treats it, and returns it. EBOO was developed to move past that ceiling, and it processes up to 4,800 mL of heparinized blood in about an hour of extracorporeal circulation.
Doing that safely took real engineering. The gas exchange devices built for it use microporous, ozone-resistant cellulose triacetate tubes, with the gas mixture flowing countercurrent inside the fibers. Purpose-built equipment, not a repurposed dialyzer.
Patients ask me what comes out. The honest answer is more interesting than the marketing version.
In December 2025, a case report in Cureus documented an 88-year-old woman with elevated urinary mycotoxins, heavy metals, and environmental toxins who underwent two series of three EBOO sessions with lab measurement at baseline and after each series. From baseline to completion, average urinary levels fell 64.8 percent for mycotoxins, 55.1 percent for environmental toxins, and 25.7 percent for heavy metals. The authors describe it as the first report of direct toxin measurement before and after EBOO.
Now the caveats, which you will not find on most clinic pages. Single patient, no control for ongoing exposure, and she lived in a 1930s building with original plumbing. One metal, nickel, rose rather than fell. Her hemoglobin did not meaningfully change. This is a first direct measurement pointing somewhere promising, in one person. It is not proof that EBOO removes toxins generally, and the authors say so in calling for larger studies.
There is more here than skeptics acknowledge and less than enthusiasts claim.
A controlled trial published in 2005 randomized 28 patients with peripheral artery disease to EBOO or intravenous prostacyclin. The EBOO group showed significant regression of skin lesions compared with prostacyclin, along with differences in pain, itching, heavy legs, and general well-being.
The most intriguing finding was what did not change. Arterial circulation was not measurably different, leading the investigators to conclude some other mechanism was responsible. That fits the signaling model rather than a plumbing model.
It is a small trial and it is twenty years old, and it deserves both qualifiers. There is also preclinical work, including a 2025 porcine study of extracorporeal ozone in septic shock, which is promising and is not a human indication.
If you are evaluating any blood filtration therapy, at my practice or anywhere else, these questions separate a serious clinic from a sales pitch:
That last point is why my practice starts with a comprehensive diagnostic workup rather than a procedure. A therapy without a baseline is an expense you cannot evaluate.
There is a defensible middle ground between two bad options, and most of this industry occupies neither.
The first is to market emerging therapies as though the evidence were settled, quoting response rates nobody has established.
The second is to dismiss anything not yet in a guideline. Hemodialysis was experimental once, and so was lipoprotein apheresis. Categorical dismissal is not rigor, and here it ignores measured biochemistry, a purpose-built device literature, a small controlled trial, and the first direct toxin measurements published.
The middle ground: describe the mechanism accurately, state the evidence level honestly including where it is thin, control the dose, screen carefully, measure before and after, price transparently, and let the patient decide. That is the standard I hold my own practice to when patients ask about EBOO therapy in Florida, and it is the standard I would want applied to me as a patient.
A century of blood filtration produced some of the most valuable therapies in medicine, and it did so by grading each indication separately rather than generalizing. EBOO is early in that process, not outside it.
Your Biological Age Test Is Less Precise Than You Think
The Question About Regenerative Injections That Almost Nobody Asks
What a Century of Blood Filtration Taught Me About Judging a New Therapy
What I Tell Patients Whose Lyme Symptoms Never Went Away
Regenerative Injections: Unlocking the Healing Power of PRP and MSC Therapy
